LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
McGlynn, L.M.; Kirkegaard, T.; Edwards, J.; Tovey, S.; Cameron, D.; Twelves, C.; Bartlett, J.M.S.; Cooke, T.G. (2009)
Publisher: American Association for Cancer Research
Languages: English
Types: Article
Subjects: RC
Purpose: The expression and activation of the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathway plays an important role in the development and progression of cancer, and may influence response to treatments such as tamoxifen and chemotherapy. In this study we investigated whether the expression and activation of the key components of this pathway influenced clinical outcome, to test the hypothesis that activation of the MAPK pathway drives resistance to tamoxifen and chemotherapy in women with breast cancer.\ud \ud Experimental Design: Breast tumors from patients at the Glasgow Royal Infirmary and others treated within the BR9601 trial were analyzed for expression of the three Ras isoforms, total Raf-1, active and inactive forms of Raf-1 [pRaf(ser338) and pRaf(ser259), respectively], MAPK, and phospho-MAPK using an immunohistochemical approach. Analyses were done with respect to disease free-survival and overall survival.\ud \ud Results: Expression and activation of the Ras pathway was associated with loss of benefit from treatment with tamoxifen but not chemotherapy. Overexpression of pRaf(ser338) was associated with shortened disease-free and overall survival time in univariate analyses. Multivariate analysis suggested pRaf(ser338) was independent of known prognostic markers in predicting outcome following tamoxifen treatment (P=0.03).\ud \ud Conclusion: This study suggests that activation of the Ras pathway predicts for poor outcome on tamoxifen but not chemotherapy, and identifies pRaf(ser338) as a potential marker of resistance to estrogen receptor–targeted therapy. In addition, it suggests that expression of pRaf(ser338) could identify patients for whom tamoxifen alone is insufficient adjuvant systemic therapy, but for whom the addition of chemotherapy may be of benefit.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351 Pt 2:289-305.
    • 2. Reese DM and Slamon D. J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1-8.
    • 3. Yarden Y and Sliwkowski M. X. Untangling the ErbB Signalling Network. Nature Reviews:- Molecular Cell Biology 2001;2:127-37.
    • 4. Adjei AA. Blocking Oncogenic Ras Signaling for Cancer Therapy. Journal of the National Cancer Institute 2001;93:1062-74.
    • 5. Macaluso M, Russo G., Cinti C., Bazan V., Gebbia N., and Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 2002;192:125- 30.
    • 6. Pruitt K and Der C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001;171:1-10.
    • 7. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
    • 8. Burgering BM and Bos J. L. Regulation of Ras-mediated signalling: more than one way to skin a cat. Trends Biochem Sci 1995;20:18-22.
    • 9. Roskoski R, Jr. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 2003;303:1-7.
    • 10. Dhillon AS and Kolch W. Untying the regulation of the Raf-1 kinase. Archives of Biochemistry and Biophysics 2002;404:3-9.
    • 11. Xing H, Kornfeld K., and Muslin A. J. The protein kinase KSR interacts with 14- 3-3 protein and Raf. Current Biology 1997;7:294-300.
    • 12. Dhillon AS, Meikle S., Yazici Z., Eulitz M., and Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 2002;21:64-71.
    • 13. Therrien M, Michaud N. R., Rubin G. M., and Morrison D. K. KSR modulates signal propagation within the MAPK cascade. Genes Dev 1996;10:2684-95.
    • 14. Santen RJ, Song Robert Xinde, McPherson Robertet al. The role of mitogenactivated protein (MAP) kinase in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 2002;80:239-56.
    • 15. Silvius JR. Mechanisms of Ras Protein Targeting in Mammalian Cells. The Journal of Membrane Biology 2002;190:83-92.
    • 16. Chen D, Washbrook E., Sarwar N.et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation specific antisera. Oncogene 2002;21:4921-31.
    • 17. Kato S, Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
    • 18. Driggers PH and Segars J. H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends In Endocrinology And Metabolism 2002;13:422-8.
    • 19. Lannigan DA. Estrogen receptor phosphorylation. Steroids 2003;68:1-9.
    • 20. Shiau AK, Barstad D., Loria P. M.et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
    • 21. Kong EH, Pike A. C. W., and Hubbard R. E. Structure and mechanism of the oestrogen receptor. Biochemical Society Transactions 2003;31:56-9.
    • 22. Poole CJ, Earl H. M., Hiller L.et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851-62.
    • 23. Amadori D, Volpi A., Maltoni R.et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997;43:7-14.
    • 24. Rees M, Stahl M., Klump B., Willers R., Gabbert H. E., and Sarbia M. The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma. Anticancer Res 2001;21:3637-42.
    • 25. Weinstein-Oppenheimer CR, Henriquez-Roldan C. F., Davis J. M.et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898-907.
    • 26. Davis JM, Navolanic P. M., Weinstein-Oppenheimer C. R.et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003;9:1161-70.
    • 28. Guise S, Braguer D., Carles G., Delacourte A., and Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer druginduced apoptosis in neuroblastoma cells. J Neurosci Res 2001;63:257-67.
    • 29. Hall JM, Couse J. F., and Korach K. S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-72.
    • 31. Kato S, Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
    • 32. Kato S, Endoh H., Masuhiro Y.et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase. Science 1995;270(5241):1491-4.
    • 33. Chung YL, Sheu M. L., Yang S. C., Lin C. H., and Yen S. H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-12.
    • 34. Osborne CK and Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12:362-7.
    • 35. Kurokawa H, Lenferink A. E., Simpson J. F.et al. Inhibition of HER2/neu (erbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2- overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
    • 36. Nicholson RI, Hutcheson I. R., Britton D.et al. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 2005;93:257-62.
    • 37. Britton DJ, Hutcheson I. R., Knowlden J. M.et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006;96:131-46.
    • 38. Tovey S, Dunne B., Witton C. J., Forsyth A., Cooke T. G., and Bartlett J. M. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005;11:4835-42.
    • 39. Tovey S, Dunne B., Witton C. J., Forsyth A., Cooke T. G., and Bartlett J. M. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005;11:4835-42.
    • 40. Mukherjee R, Bartlett J. M., Krishna N. S., Underwood M. A., and Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005;64:101-7.
    • 41. Kirkegaard T, Edwards J., Tovey S.et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006;48:787-94.
    • 42. Mukherjee R, Bartlett J. M., Krishna N. S., Underwood M. A., and Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005;64:101-7.
    • 43. Poole CJ, Earl H. M., Hiller L.et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355:1851-62.
    • 44. Lee M, Koh W. S., and Han S. S. Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett 2003;193:57-64.
    • 45. El-Ashry D, Miller D. L., Kharbanda S., Lippman M. E., and Kern F. G. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogenindependent growth and apoptosis. Oncogene 1997;15:423-35.
    • 46. Mercer K, Giblett S., Oakden A., Brown J., Marais R., and Pritchard C. A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression. Oncogene 2005;24:5207-17.
    • 47. Leng Q and Mixson A. J. Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2005;12:682-90.
    • 48. Osborne CK, Shou Jiang, Massarweh Suleiman, and Schiff Rachel. Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer. Clin Cancer Res 2005;11:865s-870.
    • 49. Kurokawa H, Lenferink A. E., Simpson J. F.et al. Inhibition of HER2/neu (erbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2- overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
    • 50. Mouridsen HT, Keshaviah A., Mauriac L.et al. BIG 1-98: A randomized doubleblind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Journal of Clinical Oncology 2006;24:10S.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article